Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.48 |
| ▸ | RARB | P10826 | 4/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP7 | P09237 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8313376 | 0.85 | MMP13 (0.46) | MMP13RARBMMP1CYP1A2CYP3A4 | |
| SCHEMBL6205985 | 0.81 | CYP2D6 (0.49) | MMP13RARBMMP1CYP1A2CYP3A4 | |
| SCHEMBL6206170 | 0.78 | L3MBTL1 (0.47) | MMP13RARBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14569172 | 0.76 | NPC1 (0.50) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3255184 | 0.75 | NPC1 (0.49) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6206523 | 0.74 | MMP13 (0.53) | MMP13MMP1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3255085 | 0.74 | MMP13 (0.49) | MMP13MMP1MMP2MMP3MMP7 | |
| SCHEMBL6538561 | 0.74 | RARB (0.76) | RARBPLA2G4B | |
| SCHEMBL16552630 | 0.73 | CYP2D6 (0.58) | RARBCYP1A2CYP3A4CYP2D6PLA2G4B | |
| SCHEMBL2355811 | 0.73 | RARB (0.79) | RARBPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565459-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | MMP13 2/4885RARB 4208/4885MMP1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.